ALZHEIMER AGENTS

A. FDA approved indications (see Table 1)
   1. Alzheimer’s dementia, mild to moderate type (Donepezil, Galantamine, Rivastigmine, Tacrine)
   2. Alzheimer’s dementia, moderate to severe type (Donepezil, Memantine, Memantine/donepezil)

B. Non-FDA approved, commonly used indications
   1. Dementia (Memantine)
   2. Dementia NOS
   3. Prophylaxis-impaired cognition (Donepezil)
   4. Dementia secondary to other medical conditions i.e. Huntington, HIV, Infection, TBI, Hypothyroidism, Vitamin B12 Deficiency
   5. Vascular dementia (Formerly Multi-Infarct Dementia)
   6. Substance-Induced Persisting Dementia

C. Minimal documentation
   1. Mini-Mental Status Examination (Folstein) at baseline if < 24, repeat each visit (no less than q6 months).
   2. R/O other etiologies such as MDD (pseudodementia)

D. Maximum Dosage - see Medication Summary for MDD

E. Duration
   1. For Outpatient: Document rationale when making any medication change.
   2. For Inpatient: Document rationale when making more than 3 changes in any 7-day period.

F. Drug-Drug Interactions – Refer to www.epocrates.com

G. Warnings & Precautions
   - Caution if cardiac conduction defects
   - Caution if seizer hx or risk
   - Caution if hepatic or renal impairment
   - Caution if asthma or COPD
   - Caution if GI bleeding or ulcer hx or risk
   - Caution if urinary obstruction

G. Standard laboratory and examination requirements
1. For inpatient: Basic laboratory studies on admission
2. For outpatient:
   Tacrine (Cognex): **LFTs at baseline, 4 weeks after initiation, then q3months thereafter.**
3. Additional laboratory work up should include metabolic profile, baseline TSH, B12, Folate, and RPR to r/o other possibilities interfering with cognitive status.
4. More frequent and/or additional monitoring should be considered depending on the clinical situation and whenever there is a change in the patient’s status.

Attachment: Table 1 FDA-Approved Indications and Maximum Dose
References: Epocrates, Micromedex
# ALZHEIMER’S DISEASE AGENTS

**Table 1: FDA-Approved Indications and Maximum Daily Dose**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Brand</th>
<th>Max Daily Dose</th>
<th>Mild-Moderate Dementia</th>
<th>Moderate-Severe Dementia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donepezil</td>
<td>Aricept</td>
<td>23mg</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Galantamine</td>
<td>Razadyne, Razadyne ER</td>
<td>24mg</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Memantine</td>
<td>Namenda</td>
<td>20mg</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Namenda XR</td>
<td>28mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rivastigmine</td>
<td>Exelon</td>
<td>12mg</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exelon Patch</td>
<td>13.3mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tacrine</td>
<td>Cognex</td>
<td>160mg</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Memantine/Donepezil</td>
<td>Namzaric</td>
<td>28ER/10</td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>